Seeking Alpha By: Brian Nichols 10/14/13
Pimavanserin: The Most Underestimated Blockbuster In Biotechnology
The bottom line is that as time passes, expect estimates to rise quickly for pima, which will then drive the valuation for Acadia. The current market potential for pima simply does not reflect the valuation of the PDP indication let alone ADP and Schzo. Therefore, unprecedented gains are likely. And for those of you hoping for a buyout or a substantial partnership, I'd cross your fingers and pray that management does not yet
entertain such offers. Due to the disruptive nature of pima, many leading pharmaceutical companies are going to lose billions because of pima, which means Acadia is likely already speaking with or is being assessed by a handful of large companies. However, this is a company that simply has too much upside fora 100% premium right now, and over the next year as peak sales estimate rise, you will see that any price under $50 is cheap
added more today, knew this was a joke in the $20,, will see 4100 on this one.
Seen this 1,000 times in trading. Will be back over $3 by Monday. Great buy opportunity.
We Never Crashed and Some Last Quarter Set Ups
October 12th, 2013
$CLDX I like that Celdex tested and held the 50 day moving average twice. I still see 40+ on this one.
$ 20's ???? This will be one in the $100's and investors will say why didn't I buy that.
Mobile ads on the rise: US advertisers spent $3b in first half of 2013, up 60% on last year
As consumers are increasingly connecting to the Internet via their smartphones, advertisers are piling on the money to roll out mobile ads. In the first half of 2013, US advertisers spent $3 billion on mobile advertising, up from $1.2 billion a year earlier, according to estimates from the Interactive Advertising Bureau, the Wall Street Journal reports.
The share of mobile ad expenditure out of total online ad spending in the US more than doubled to 15 percent during the first half of the year, the data showed. In all, US advertisers spent $20.1 billion on Internet ads during the period. Comparatively, TV ad spending will likely stand at around $66.35 billion for the whole of this year, research company eMarketer predicts
This was copied and pasted from ACAD Homepage Website:
We hold worldwide rights to pimavanserin and have established a patent portfolio, which includes
numerous issued patents covering pimavanserin in the United States, Europe and several additional countries.
We believe that pimavanserin also has the potential to address a range of other neurological and psychiatric disorders that are under served by currently available anti psychotics and represent large unmet medicalneeds. This may include treatment for psychoses associated with other neurological disorders, including Alzheimer’s disease, and as a co-therapy for schizophrenia.
do the DD.